CN100577175C - 包括葡萄糖重吸收抑制剂和ppar调节剂的联合疗法 - Google Patents

包括葡萄糖重吸收抑制剂和ppar调节剂的联合疗法 Download PDF

Info

Publication number
CN100577175C
CN100577175C CN02811137A CN02811137A CN100577175C CN 100577175 C CN100577175 C CN 100577175C CN 02811137 A CN02811137 A CN 02811137A CN 02811137 A CN02811137 A CN 02811137A CN 100577175 C CN100577175 C CN 100577175C
Authority
CN
China
Prior art keywords
glucose
ppar
insulin
rosiglitazone
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN02811137A
Other languages
English (en)
Chinese (zh)
Other versions
CN1568190A (zh
Inventor
J·C·布索拉里
X·陈
B·R·康韦
K·T·德马雷斯特
H·N·M·罗斯
R·塞维里诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3 Dimensional Pharmaceuticals Inc
Original Assignee
3 Dimensional Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3 Dimensional Pharmaceuticals Inc filed Critical 3 Dimensional Pharmaceuticals Inc
Publication of CN1568190A publication Critical patent/CN1568190A/zh
Application granted granted Critical
Publication of CN100577175C publication Critical patent/CN100577175C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/305—Mercury compounds
    • A61K31/31—Mercury compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
CN02811137A 2001-04-04 2002-04-03 包括葡萄糖重吸收抑制剂和ppar调节剂的联合疗法 Expired - Lifetime CN100577175C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28142901P 2001-04-04 2001-04-04
US60/281,429 2001-04-04

Publications (2)

Publication Number Publication Date
CN1568190A CN1568190A (zh) 2005-01-19
CN100577175C true CN100577175C (zh) 2010-01-06

Family

ID=23077253

Family Applications (1)

Application Number Title Priority Date Filing Date
CN02811137A Expired - Lifetime CN100577175C (zh) 2001-04-04 2002-04-03 包括葡萄糖重吸收抑制剂和ppar调节剂的联合疗法

Country Status (11)

Country Link
US (3) US20030045553A1 (https=)
EP (2) EP1381361B1 (https=)
JP (1) JP4590159B2 (https=)
CN (1) CN100577175C (https=)
AT (1) ATE423559T1 (https=)
CA (1) CA2442917C (https=)
DE (1) DE60231295D1 (https=)
ES (1) ES2321815T3 (https=)
MY (1) MY180762A (https=)
TW (1) TWI330084B (https=)
WO (1) WO2002080936A1 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4590158B2 (ja) 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびレチノイド−ｘ受容体モジュレーターを含んで成る併用療法
WO2002080936A1 (en) 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
US20090162342A1 (en) * 2001-06-07 2009-06-25 Sanomune Inc. Therapeutic uses of glandular kallikrein
EP1388352A1 (en) * 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Use of a ppar-alpha agonist to treat patients suffering from weight gain associated with a ppar-gamma agonist treatment
DE10258008B4 (de) * 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
JP2004300102A (ja) * 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
US7601756B2 (en) * 2003-06-06 2009-10-13 Snowden Pharmaceuticals, Llc Method of treatment for irritable bowel syndrome
KR20060105431A (ko) * 2003-06-27 2006-10-11 닥터 레디스 리서치 파운데이션 발라글리타존 및 당뇨병치료제 화합물을 포함하는 조성물
EP1662906A1 (en) * 2003-09-23 2006-06-07 DSM IP Assets B.V. Compositions for the treatment and prevention of diabetes mellitus
US20050239706A1 (en) * 2003-10-31 2005-10-27 Washington University In St. Louis Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject
US20080274193A1 (en) * 2004-01-23 2008-11-06 Japan Science And Technology Agency Retinoic Acid-Containing Antidiabetic Agent
JP4901218B2 (ja) * 2004-02-09 2012-03-21 あすか製薬株式会社 併用医薬
KR20070011379A (ko) 2004-03-17 2007-01-24 라스 미카엘 라르센 시각 사이클 억제에 의한 망막증의 예방
EP1782828B1 (en) * 2004-07-21 2016-06-29 Kissei Pharmaceutical Co., Ltd. Progression inhibitor for disease attributed to abnormal accumulation of liver fat
US7767682B2 (en) * 2005-03-03 2010-08-03 Glaxosmithkline Llc Medicaments
US20080280955A1 (en) * 2005-09-30 2008-11-13 Perlegen Sciences, Inc. Methods and compositions for screening and treatment of disorders of blood glucose regulation
EP1785133A1 (en) * 2005-11-10 2007-05-16 Laboratoires Fournier S.A. Use of fenofibrate or a derivative thereof for preventing diabetic retinopathy
DE102006028862A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
WO2008096769A1 (ja) * 2007-02-08 2008-08-14 Daiichi Sankyo Company, Limited 置換されたセルコスポラミド誘導体を含有する医薬
DE102007008420A1 (de) 2007-02-21 2008-08-28 Merck Patent Gmbh Benzimidazolderivate
US8666671B2 (en) * 2007-07-05 2014-03-04 Enhanced Pharmaceuticals, Inc. Method for determining drug-molecular combinations that modulate and enhance the therapeutic safety and efficacy of biological or pharmaceutical drugs
DE102007048716A1 (de) 2007-10-11 2009-04-23 Merck Patent Gmbh Imidazo[1,2-a]pyrimidinderivate
ES2541141T3 (es) * 2008-01-31 2015-07-16 Astellas Pharma Inc. Composición farmacéutica para el tratamiento de las enfermedades del hígado graso
DE102008017590A1 (de) 2008-04-07 2009-10-08 Merck Patent Gmbh Glucopyranosidderivate
MY155418A (en) * 2008-08-28 2015-10-15 Pfizer Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
EP2419097B1 (en) * 2009-04-16 2013-09-25 Taisho Pharmaceutical Co., Ltd. Pharmaceutical composition comprising (1s)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol and metformin and uses thereof in the treatment of diabetes
US20120115912A1 (en) * 2009-07-10 2012-05-10 Landreth Gary E Rxr agonist compounds and methods
KR20120091174A (ko) 2009-10-02 2012-08-17 사노피 골질환 치료제의 제조를 위한 ｓｇｌｔ-1/ｓｇｌｔ-2 억제제 활성을 갖는 화합물의 용도
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
EA021983B1 (ru) 2009-11-02 2015-10-30 Пфайзер Инк. Производные диоксабицикло[3.2.1]октан-2,3,4-триола
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
ES2667854T3 (es) * 2011-07-07 2018-05-14 Holy Stone Healthcare Co., Ltd. Composición para uso en el tratamiento y la prevención de trastornos relacionados con la inflamación
US9451987B2 (en) 2011-11-16 2016-09-27 K2M, Inc. System and method for spinal correction
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
EP2854841B1 (en) 2012-06-04 2017-02-22 Diamedica Inc. Human tissue kallikrein 1 glycosylation isoforms
CN102727477B (zh) * 2012-06-14 2014-07-16 合肥博太医药生物技术发展有限公司 视黄酸及其衍生物在制备防治糖尿病药物中的应用
EP2774619B1 (de) 2013-03-04 2016-05-18 BioActive Food GmbH Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
EP2944311A1 (de) 2014-05-16 2015-11-18 BioActive Food GmbH Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
CN110446501A (zh) 2017-03-09 2019-11-12 代阿麦迪卡股份有限公司 组织激肽释放酶1的剂型
CN111511402A (zh) * 2017-12-28 2020-08-07 国立大学法人福井大学 白内障的预防剂及/或治疗剂、用于预防及/或治疗白内障的医药组合物、ppar活化剂的用于制造它们的用途、以及滴眼剂
CN111437393B (zh) * 2020-04-30 2021-03-02 深圳微芯生物科技股份有限公司 用于糖尿病及其并发症治疗的联合用药及其药物组合物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424406A (en) * 1992-11-12 1995-06-13 Tanabe Seiyaku Co., Ltd. Dihydrochalcone derivatives which are hypoglycemic agents
US5731292A (en) * 1992-11-12 1998-03-24 Tanabe Seiyaku Co., Ltd. Dihydrochalcone derivatives which are hypoglycemic agents
US5767094A (en) * 1995-11-07 1998-06-16 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and processes for preparing the same
US5830873A (en) * 1994-05-11 1998-11-03 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and a process for preparing the same
US6048842A (en) * 1996-12-26 2000-04-11 Tanabe Seiyaku Co., Ltd. Propiophenone derivatives and process for preparing the same
CN1407990A (zh) * 1999-10-12 2003-04-02 布里斯托尔-迈尔斯斯奎布公司 C－芳基葡糖苷sglt2抑制剂

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
SG59988A1 (en) * 1987-09-04 1999-02-22 Beecham Group Plc Substituted thiazolidinedione derivatives
JPH0253573A (ja) * 1988-08-11 1990-02-22 Nippon Riki Kk ラチェットレンチの製造法
US5731299A (en) 1992-05-29 1998-03-24 The Procter & Gamble Company Phosphonosulfonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism
JP2762903B2 (ja) 1992-11-12 1998-06-11 田辺製薬株式会社 ジヒドロカルコン誘導体及びその製法
JP2795162B2 (ja) 1993-02-18 1998-09-10 田辺製薬株式会社 ジヒドロカルコン誘導体及びその製法
JP2906978B2 (ja) 1993-02-25 1999-06-21 田辺製薬株式会社 血糖降下剤
US6046222A (en) 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
JP2847695B2 (ja) * 1994-05-11 1999-01-20 田辺製薬株式会社 血糖降下剤
ATE259227T1 (de) 1995-09-18 2004-02-15 Ligand Pharm Inc Behandlung von niddm (nichtinsulinabhängige diabetes mellitus) mit rxr agonisten
EP0921798A1 (en) * 1996-07-12 1999-06-16 Smithkline Beecham Plc Novel treatment of leptine resistance
JP3055135B2 (ja) * 1996-12-26 2000-06-26 田辺製薬株式会社 プロピオフェノン誘導体及びその製法
US6153632A (en) 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
JP4100734B2 (ja) 1997-04-30 2008-06-11 Ｓａｂｉｃイノベーティブプラスチックスジャパン合同会社 熱可塑性樹脂組成物
AU8799998A (en) 1997-06-18 1999-01-04 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
JP2000080041A (ja) 1998-03-09 2000-03-21 Tanabe Seiyaku Co Ltd 医薬組成物
JP3784001B2 (ja) * 1998-11-20 2006-06-07 三菱化学株式会社 ５−［｛６−（２−フルオロベンジル）オキシ−２−ナフチル｝メチル］−２，４−チアゾリジンジオンの結晶体
US6337426B1 (en) 1998-11-23 2002-01-08 Nalco/Exxon Energy Chemicals, L.P. Antifoulant compositions and processes
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
AU4649600A (en) 1999-04-22 2000-11-10 Joel F. Habener Bridge-1, a transcription factor
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
ATE264337T1 (de) 1999-08-31 2004-04-15 Kissei Pharmaceutical Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung
NZ517993A (en) 1999-08-31 2004-03-26 Incyte San Diego Inc Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes
PE20010580A1 (es) 1999-09-03 2001-05-25 Takeda Chemical Industries Ltd Composicion farmaceutica para tratar la diabetes
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
JP2001192375A (ja) * 1999-10-29 2001-07-17 Takeda Chem Ind Ltd オキシイミノアルカン酸誘導体の結晶
TW558554B (en) 1999-10-29 2003-10-21 Takeda Chemical Industries Ltd Crystals of oxyiminoalkanoic acid derivative
HK1045991B (en) * 1999-11-10 2004-12-10 Takeda Pharmaceutical Company Limited 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) * 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
MXPA03003870A (es) 2000-10-30 2004-08-12 Johnson & Johnson Terapia de combinacion que comprende agentes antidiabeticos y anticonvulsionantes.
PL209375B1 (pl) 2000-12-28 2011-08-31 Kissei Pharmaceutical Pochodne glukopiranozyloksypirazolu, kompozycja farmaceutyczna zawierająca takie pochodne i zastosowanie tych pochodnych do wytwarzania kompozycji farmaceutycznej
JP4590158B2 (ja) 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびレチノイド−ｘ受容体モジュレーターを含んで成る併用療法
WO2002080936A1 (en) 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424406A (en) * 1992-11-12 1995-06-13 Tanabe Seiyaku Co., Ltd. Dihydrochalcone derivatives which are hypoglycemic agents
US5731292A (en) * 1992-11-12 1998-03-24 Tanabe Seiyaku Co., Ltd. Dihydrochalcone derivatives which are hypoglycemic agents
US5830873A (en) * 1994-05-11 1998-11-03 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and a process for preparing the same
US5767094A (en) * 1995-11-07 1998-06-16 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and processes for preparing the same
US6048842A (en) * 1996-12-26 2000-04-11 Tanabe Seiyaku Co., Ltd. Propiophenone derivatives and process for preparing the same
CN1407990A (zh) * 1999-10-12 2003-04-02 布里斯托尔-迈尔斯斯奎布公司 C－芳基葡糖苷sglt2抑制剂

Also Published As

Publication number Publication date
WO2002080936A1 (en) 2002-10-17
EP2065044A1 (en) 2009-06-03
MY180762A (en) 2020-12-08
CA2442917A1 (en) 2002-10-17
JP2004529915A (ja) 2004-09-30
US20080096802A1 (en) 2008-04-24
US20030199557A1 (en) 2003-10-23
TWI330084B (en) 2010-09-11
JP4590159B2 (ja) 2010-12-01
US8278268B2 (en) 2012-10-02
EP1381361A1 (en) 2004-01-21
ES2321815T3 (es) 2009-06-12
EP1381361B1 (en) 2009-02-25
ATE423559T1 (de) 2009-03-15
DE60231295D1 (de) 2009-04-09
US20030045553A1 (en) 2003-03-06
CA2442917C (en) 2011-02-01
CN1568190A (zh) 2005-01-19

Similar Documents

Publication Publication Date Title
CN100577175C (zh) 包括葡萄糖重吸收抑制剂和ppar调节剂的联合疗法
CN100384430C (zh) 含有葡萄糖重吸收抑制剂和维生素a类-x受体调节剂的联合治疗
US6353009B1 (en) Method for the treatment and prevention of hyperuricemia
KR20080080220A (ko) Ｄｐｉｖ 억제제 및 메트포르민 또는 티아졸리딘디온을병용한 2형 당뇨병의 치료
Fürstenwerth Ouabain-the insulin of the heart
TWI491392B (zh) 減少較小，稠密低密度脂蛋白（ｌｄｌ）粒子之方法
CN106963761A (zh) 3,4‑二取代的吡啶化合物、其使用方法以及包含该化合物的组合物
KR20240037955A (ko) 혈당 조절 및 당뇨병 및 관련 질환의 치료 방법
KR101567660B1 (ko) 진성 당뇨병을 치료하기 위한 병용제
JP2021529728A (ja) 慢性腎疾患を持つ糖尿病対象を治療する方法
US20180353507A1 (en) Methods of preventing or treating hypoglycemia by administering a gpr119 agonist
EP1889618A1 (en) Combined drug for treating diabetes
HK1131742A (en) Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
CN109498623A (zh) 改善肝功能的方法
US10759749B2 (en) Therapeutic agent for diabetes
HK1159492B (en) Methods of reducing small, dense ldl particles

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20100106

CX01 Expiry of patent term